Pharmaceutical

Biocon’s Denosumab biosimilars gain EU marketing authorisation

Biocon Biologics’ Denosumab biosimilars, Vevzuo and Evfraxy, have received marketing authorisation in the European Union (EU).

Jul 5, 2025 - 06:00
Biocon’s Denosumab biosimilars gain EU marketing authorisation
Biocon Biologics’ Denosumab biosimilars, Vevzuo and Evfraxy, have received marketing authorisation in the European Union (EU).
Read the original article

Tags:

Previous Article

Big pharma braces for revenue headwinds as patent expiries loom

Next Article

Brii Biosciences and Joincare sign licence agreement for BRII-693

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Medical device companies now need to prove to FDA they’re protected against cyberattacks

STAT+: Medical device companies now need to prove to FD...

Mar 30, 2023

STAT+: A single drug and multiple study failures leave Anavex with nothing but cash

STAT+: A single drug and multiple study failures leave ...

Jan 2, 2024

Hasten Biopharmaceutic raises $315m for pipeline assets development

Hasten Biopharmaceutic raises $315m for pipeline assets...

Apr 20, 2023